These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 7152395)
1. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs]. Kogi K; Tanaka O; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)]. Kogi K; Chida S; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370 [TBL] [Abstract][Full Text] [Related]
3. Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs. Kogi K; Satoh T Jpn J Pharmacol; 1987 Jul; 44(3):249-57. PubMed ID: 3656782 [TBL] [Abstract][Full Text] [Related]
5. [Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate]. Murakawa T; Hashimoto Y; Sato T; Takagi H; Kushikata T; Araki I; Kou H; Kimura F; Matsuki A Masui; 1993 Feb; 42(2):225-32. PubMed ID: 8437354 [TBL] [Abstract][Full Text] [Related]
6. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group. Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515 [TBL] [Abstract][Full Text] [Related]
7. Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females. Nakatsu K; Brien JF; Savard G; Toffelmire EB; Abdollah H; Bennett BM; Marks GS Biopharm Drug Dispos; 1992 Jul; 13(5):357-67. PubMed ID: 1498268 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of isosorbide dinitrate tape on exercise tolerance of patients with angina pectoris. Saito M; Nobuyoshi M; Nakamura N; Nishiyama S; Haze K; Hiramori K; Ikeda M Arzneimittelforschung; 1983; 33(9):1301-5. PubMed ID: 6685512 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. Keller-Stanislawski B; Marschner JP; Rietbrock N Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374 [TBL] [Abstract][Full Text] [Related]
11. [Effects of isosorbide 5-mononitrate on cardiovascular function. (I). Effects on the left ventricular system]. Kogi K; Saito T Nihon Yakurigaku Zasshi; 1985 May; 85(5):335-42. PubMed ID: 4029805 [TBL] [Abstract][Full Text] [Related]
12. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524 [TBL] [Abstract][Full Text] [Related]
14. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. Menke G; Schnellhammer R; Rietbrock N Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041 [TBL] [Abstract][Full Text] [Related]
16. Effects of a sustained-release form of isosorbide dinitrate on left atrial pressure in dogs with experimentally induced mitral valve regurgitation. Yamamoto Y; Suzuki S; Hamabe L; Aytemiz D; Huai-Che H; Kim S; Yoshiyuki R; Fukayama T; Fukushima R; Tanaka R J Vet Intern Med; 2013; 27(6):1421-6. PubMed ID: 24010635 [TBL] [Abstract][Full Text] [Related]
17. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms]. Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644 [TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
19. Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions. Morrison RA; Fung HL J Pharmacol Exp Ther; 1984 Oct; 231(1):124-30. PubMed ID: 6491969 [TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. Laufen H; Leitold M; Wildfeuer A Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]